{
    "clinical_study": {
        "@rank": "51838", 
        "arm_group": [
            {
                "arm_group_label": "Carvedilol SR 32mg, 64mg", 
                "arm_group_type": "Experimental", 
                "description": "\u2022Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks."
            }, 
            {
                "arm_group_label": "Carvedilol IR 25mg", 
                "arm_group_type": "Active Comparator", 
                "description": "\u2022Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of present study is to evaluate the efficacy and safety of Carvedilol SR versus\n      Carvedilol IR in Patients With Essential Hypertension"
        }, 
        "brief_title": "Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "-  In patients with Essential hypertension to evaluate the efficacy and safety of\n           Carvedilol SR (32mg, 64mg) or Carvedilol IR (25mg QD, 25mg BID) during 8 weeks.\n\n        -  This study is consist of placebo run-in period(2~4 weeks_single blind) and treatment\n           period(8 weeks_double blind)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age 18 years or older\n\n          -  at the screening visit(visit 1)\n\n               -  antihypertensive drugs not taking: 90mmHg \u2264 mean sitDBP \u2264 109mmHg and mean\n                  sitSBP < 180mmHg\n\n               -  antihypertensive drugs taking: mean sitDBP \u2264 104mmHg and mean sitSBP < 180mmHg\n\n          -  at the randomization visit(visit 2): 90mmHg \u2264 mean sitDBP \u2264 109mmHg and mean sitSBP <\n             180mmHg\n\n          -  willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          1. At Screening, difference in measured blood pressure  of the selected arm(sitDBP \u2265\n             10mmHg or sitSBP \u2265 20mmHg)\n\n          2. known or suspected secondary hypertension(ex. aortic coarctation, Primary\n             hyperaldosteronism, renal artery stenosis, pheochromocytoma)\n\n          3. Type I Diabetes Mellitus, Type II Diabetes Mellitus with poor glucose control as\n             defined by fasting glucosylated hemoglobin(HbA1c > 9%)\n\n          4. Corresponding to the following\n\n               -  has severe heart disease(Heart failure NYHA functional class 3, 4)\n\n               -  ischaemic heart diseases within 6 months (unstable angina or myocardial\n                  infarction)\n\n               -  myocardiopathy\n\n               -  Cor pulmonale\n\n               -  aortic stenosis , aortic valvular stenosis , mitral stenosis\n\n               -  abnormality of the conduction system as  2nd degree AV block, Complete AV block,\n                  Sick Sinus Syndrome, Sinus Block(In particular, pulse <50beats / min)\n\n               -  has heart attack with complication.\n\n          5. has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6\n             months\n\n          6. has edema glottitis, allergic rhinitis, Respiratory diseases as Asthma, Chronic\n             Obstructive Pulmonary Disease.\n\n          7. Peripheral circulatory disturbance( ex. Raynaud syndrome, intermittent claudication)\n\n          8. Fluid retention or overload to required intravenous inotropes.\n\n          9. known severe or malignant retinopathy(retinal hemorrhage, visual disturbance, Retinal\n             microaneurysms and so on within 6 months)\n\n         10. defined by the following laboratory parameters:\n\n               -  hepatic dysfunction(AST/ALT \u2265 UNL X 3)\n\n               -  renal dysfunction(serum creatinine \u2265 UNL X 2)\n\n         11. any surgical or medical condition which might significantly alter the absorption,\n             distribution, metabolism, or excretion of investigational products(ex.\n             gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass,\n             active inflammatory bowel syndrome within 12 months prior to screening, gastric\n             ulcers need to treatment, gastrointestinal/rectal bleeding, impaired pancreatic\n             function such as pancreatitis, obstructions of the urinary tract or difficulty in\n             voiding)\n\n         12. history of drug or alcohol dependency within 6 months\n\n         13. premenopausal women(last menstruation < 12 months) not using adequate contraception,\n             pregnant or breast-feeding\n\n         14. chronic inflammatory status need to treatment\n\n         15. known hypersensitivity related to carvedilol\n\n         16. history of malignancy including leukemia and lymphoma within the past 5 years\n\n         17. administration of other study drugs within 28 days prior to the first IP\n             administration\n\n         18. in investigator's judgment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "238", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756430", 
            "org_study_id": "125HT12001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Carvedilol SR 32mg, 64mg", 
                "description": "Carvedilol SR 32mg QD for 4 weeks\nWith the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.", 
                "intervention_name": "Carvedilol SR 32mg, QD", 
                "intervention_type": "Drug", 
                "other_name": "Dilatrend SR"
            }, 
            {
                "arm_group_label": "Carvedilol SR 32mg, 64mg", 
                "description": "Carvedilol SR 64mg QD for 4 weeks\nWith the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.", 
                "intervention_name": "Carvedilol SR 64mg, QD", 
                "intervention_type": "Drug", 
                "other_name": "Dilatrend SR"
            }, 
            {
                "arm_group_label": "Carvedilol IR 25mg", 
                "description": "Carvedilol IR 25mg QD for 4 weeks\nWith the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks.", 
                "intervention_name": "Carvedilol IR 25mg, QD", 
                "intervention_type": "Drug", 
                "other_name": "Dilatrend IR"
            }, 
            {
                "arm_group_label": "Carvedilol IR 25mg", 
                "description": "Carvedilol IR 25mg BID for 4 weeks\nWith the others investigation product placebo 2 capsules QD for 4 weeks.", 
                "intervention_name": "Carvedilol IR 25mg, BID", 
                "intervention_type": "Drug", 
                "other_name": "Dilatrend IR"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carvedilol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Carvedilol SR", 
            "Carvedilol IR", 
            "Hypertension", 
            "Essential Hypertension"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Guri-si", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "471-701"
                }, 
                "name": "The Hanyang Universitiy Guri Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension", 
        "overall_official": [
            {
                "affiliation": "The Hanyang Universitiy Guri Hospital", 
                "last_name": "Soon Kill Kim", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University of Korea Bucheon St.Mary's Hospital", 
                "last_name": "Sang-Hyun Ihm", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University of Korea, Seoul St. Vincent's Hospital", 
                "last_name": "Sang Hong Haek", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyunghee University Medical Center", 
                "last_name": "Jin-Bae Kim", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "NHIC Ilsan hospital", 
                "last_name": "Dong Woon Jeon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Keimyung University, Donsan Hospital", 
                "last_name": "Chang-Wook Nam", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul National University Bundang Hospital", 
                "last_name": "Dong-Ju Choi", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Soon Chun Hyang University Hospital", 
                "last_name": "Min Su Hyon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Sejong General Hospital", 
                "last_name": "Young Jin Choi", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gangnam Severance Hospital", 
                "last_name": "Hyuck Moon Kwon", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Yonsei University Severance Hospital", 
                "last_name": "Geu Ru Hong", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wonju Severance Christian Hospital", 
                "last_name": "Byung-Su Yoo", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Jesus hospital", 
                "last_name": "Ji-Hyun Lim", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Young Keun Ahn", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hanyang University Seoul Hospital", 
                "last_name": "Jin Ho Shin", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean Sitting Diastolic Blood Pressure (MSDBP)", 
            "safety_issue": "No", 
            "time_frame": "After 4 and 8 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Sitting systolic Blood Pressure (MSSBP)", 
                "safety_issue": "No", 
                "time_frame": "After  4 weeks and 8 weeks of treatment"
            }, 
            {
                "description": "Sitting DBP<90mmHg, Sitting SBP<140mmHg", 
                "measure": "Control Rate", 
                "safety_issue": "No", 
                "time_frame": "After 8 weeks of treatment"
            }, 
            {
                "description": "Reduction of Sitting DBP\u226510mmHg, Sitting SBP \u226520mmHg", 
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "After 8 weeks of treatment"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}